Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unesbulin + Chemo in Ovarian Cancer
NCT03206645Phase 1Completed
- Sponsor
- University of Oklahoma
- Start
- Aug 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of unesbulin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University of Oklahoma. Primary endpoints: Maximum Tolerated Dose at 42 days, Number of patients able to tolerate drug combination at 3 years and 1 more. Started Aug 2017; status: completed.
02
Drugs
unesbulin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03206645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206645.